STOCK TITAN

[SCHEDULE 13G/A] Intensity Therapeutics, Inc. Common stock SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Schedule 13G/A filed for Intensity Therapeutics, Inc. (INTS) reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 1,237,113 shares of the issuer's common stock, representing 2.56% of the class. The filing states Armistice Capital is the investment manager of the Master Fund, the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over the reported shares. Mr. Boyd, as managing member, is likewise reported with shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to its Investment Management Agreement.

Dichiarazione Schedule 13G/A per Intensity Therapeutics, Inc. (INTS) indica che Armistice Capital, LLC e Steven Boyd possiedono collettivamente in via beneficiaria 1.237.113 azioni del capitale sociale dell'emittente, pari al 2,56% della classe. Il deposito precisa che Armistice Capital è il gestore degli investimenti del Master Fund, detentore diretto delle azioni, e che Armistice esercita poteri condivisi di voto e di disposizione sulle azioni segnalate. Anche il sig. Boyd, in qualità di membro amministratore, risulta esercitare poteri condivisi di voto e di disposizione. Il Master Fund nega la titolarità beneficiaria diretta a causa del suo Accordo di Gestione degli Investimenti.

Presentación Schedule 13G/A para Intensity Therapeutics, Inc. (INTS) informa que Armistice Capital, LLC y Steven Boyd poseen colectivamente con carácter beneficiario 1.237.113 acciones de las acciones ordinarias del emisor, lo que representa el 2,56% de la clase. La presentación indica que Armistice Capital es el gestor de inversiones del Master Fund, titular directo de las acciones, y que Armistice ejerce poderes compartidos de voto y disposición sobre las acciones notificadas. El Sr. Boyd, como miembro gerente, también figura con poderes compartidos de voto y disposición. El Master Fund niega la propiedad beneficiaria directa debido a su Acuerdo de Gestión de Inversiones.

Intensity Therapeutics, Inc. (INTS)에 대한 Schedule 13G/A 제출에 따르면 Armistice Capital, LLC와 Steven Boyd는 집단적으로 발행회사의 보통주 1,237,113주를 실질적으로 보유하고 있으며 이는 전체 종류의 2.56%에 해당합니다. 제출서에는 Armistice Capital이 주식을 직접 보유한 Master Fund의 투자 관리자이며, 보고된 주식에 대해 공동의 의결권 및 처분권을 행사한다고 기재되어 있습니다. Boyd 씨도 매니징 멤버로서 공동의 의결권 및 처분권을 행사하는 것으로 보고됩니다. Master Fund는 투자관리계약(Investment Management Agreement)으로 인해 직접적 실질 소유권을 부인합니다.

Déclaration Schedule 13G/A déposée pour Intensity Therapeutics, Inc. (INTS) rapporte qu'Armistice Capital, LLC et Steven Boyd détiennent collectivement à titre bénéficiaire 1 237 113 actions des actions ordinaires de l'émetteur, représentant 2,56 % de la catégorie. Le dépôt précise qu'Armistice Capital est le gestionnaire d'investissement du Master Fund, détenteur direct des actions, et qu'Armistice exerce des pouvoirs partagés de vote et de disposition sur les actions déclarées. M. Boyd, en tant que membre dirigeant, est également indiqué comme exerçant des pouvoirs partagés de vote et de disposition. Le Master Fund décline toute propriété bénéficiaire directe en raison de son accord de gestion d'investissement.

Schedule 13G/A für Intensity Therapeutics, Inc. (INTS) eingereicht berichtet, dass Armistice Capital, LLC und Steven Boyd gemeinschaftlich wirtschaftlich 1.237.113 Aktien des emittierenden Unternehmens besitzen, was 2,56% der Klasse entspricht. Die Einreichung gibt an, dass Armistice Capital der Investmentmanager des Master Fund ist, der direkte Inhaber der Aktien, und dass Armistice über die gemeldeten Aktien gemeinsame Stimm- und Verfügungsbefugnisse ausübt. Herr Boyd wird als geschäftsführendes Mitglied ebenfalls mit gemeinsamen Stimm- und Verfügungsbefugnissen angegeben. Der Master Fund weist aufgrund seines Investment Management Agreement eine direkte wirtschaftliche Eigentümerschaft zurück.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Armistice and its managing member report a modest 2.56% shared stake, a routine disclosure with limited market impact.

This Schedule 13G/A confirms a passive ownership disclosure rather than an activist or control-seeking filing: the stake is below 5% and is reported as shared voting/dispositive power through an investment manager arrangement. For investors, this is transparency about an institutional exposure but not a material ownership shift likely to change control or strategy.

TL;DR: The filing documents appropriate joint reporting and allocation of voting/dispositive authority under an investment management agreement.

The filing clarifies roles: Armistice Capital as investment manager and Steven Boyd as managing member disclose shared authority over the Master Fund's holdings and include the Master Fund's disclaimer of direct beneficial ownership due to the management agreement. This aligns with standard governance disclosures and joint-filing practices, reducing ambiguity about who exercises voting rights.

Dichiarazione Schedule 13G/A per Intensity Therapeutics, Inc. (INTS) indica che Armistice Capital, LLC e Steven Boyd possiedono collettivamente in via beneficiaria 1.237.113 azioni del capitale sociale dell'emittente, pari al 2,56% della classe. Il deposito precisa che Armistice Capital è il gestore degli investimenti del Master Fund, detentore diretto delle azioni, e che Armistice esercita poteri condivisi di voto e di disposizione sulle azioni segnalate. Anche il sig. Boyd, in qualità di membro amministratore, risulta esercitare poteri condivisi di voto e di disposizione. Il Master Fund nega la titolarità beneficiaria diretta a causa del suo Accordo di Gestione degli Investimenti.

Presentación Schedule 13G/A para Intensity Therapeutics, Inc. (INTS) informa que Armistice Capital, LLC y Steven Boyd poseen colectivamente con carácter beneficiario 1.237.113 acciones de las acciones ordinarias del emisor, lo que representa el 2,56% de la clase. La presentación indica que Armistice Capital es el gestor de inversiones del Master Fund, titular directo de las acciones, y que Armistice ejerce poderes compartidos de voto y disposición sobre las acciones notificadas. El Sr. Boyd, como miembro gerente, también figura con poderes compartidos de voto y disposición. El Master Fund niega la propiedad beneficiaria directa debido a su Acuerdo de Gestión de Inversiones.

Intensity Therapeutics, Inc. (INTS)에 대한 Schedule 13G/A 제출에 따르면 Armistice Capital, LLC와 Steven Boyd는 집단적으로 발행회사의 보통주 1,237,113주를 실질적으로 보유하고 있으며 이는 전체 종류의 2.56%에 해당합니다. 제출서에는 Armistice Capital이 주식을 직접 보유한 Master Fund의 투자 관리자이며, 보고된 주식에 대해 공동의 의결권 및 처분권을 행사한다고 기재되어 있습니다. Boyd 씨도 매니징 멤버로서 공동의 의결권 및 처분권을 행사하는 것으로 보고됩니다. Master Fund는 투자관리계약(Investment Management Agreement)으로 인해 직접적 실질 소유권을 부인합니다.

Déclaration Schedule 13G/A déposée pour Intensity Therapeutics, Inc. (INTS) rapporte qu'Armistice Capital, LLC et Steven Boyd détiennent collectivement à titre bénéficiaire 1 237 113 actions des actions ordinaires de l'émetteur, représentant 2,56 % de la catégorie. Le dépôt précise qu'Armistice Capital est le gestionnaire d'investissement du Master Fund, détenteur direct des actions, et qu'Armistice exerce des pouvoirs partagés de vote et de disposition sur les actions déclarées. M. Boyd, en tant que membre dirigeant, est également indiqué comme exerçant des pouvoirs partagés de vote et de disposition. Le Master Fund décline toute propriété bénéficiaire directe en raison de son accord de gestion d'investissement.

Schedule 13G/A für Intensity Therapeutics, Inc. (INTS) eingereicht berichtet, dass Armistice Capital, LLC und Steven Boyd gemeinschaftlich wirtschaftlich 1.237.113 Aktien des emittierenden Unternehmens besitzen, was 2,56% der Klasse entspricht. Die Einreichung gibt an, dass Armistice Capital der Investmentmanager des Master Fund ist, der direkte Inhaber der Aktien, und dass Armistice über die gemeldeten Aktien gemeinsame Stimm- und Verfügungsbefugnisse ausübt. Herr Boyd wird als geschäftsführendes Mitglied ebenfalls mit gemeinsamen Stimm- und Verfügungsbefugnissen angegeben. Der Master Fund weist aufgrund seines Investment Management Agreement eine direkte wirtschaftliche Eigentümerschaft zurück.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

INTENSITY THERAPEUTICS INC

NASDAQ:INTS

INTS Rankings

INTS Latest News

INTS Latest SEC Filings

INTS Stock Data

13.65M
40.82M
23.91%
10.08%
1.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SHELTON